KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Intangibles (2016 - 2025)

Eli Lilly (LLY) has disclosed Intangibles for 14 consecutive years, with $6.4 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 1.39% year-over-year to $6.4 billion, compared with a TTM value of $6.4 billion through Sep 2025, down 1.39%, and an annual FY2024 reading of $6.2 billion, down 10.72% over the prior year.
  • Intangibles was $6.4 billion for Q3 2025 at Eli Lilly, up from $5.9 billion in the prior quarter.
  • Across five years, Intangibles topped out at $8.1 billion in Q1 2021 and bottomed at $5.9 billion in Q2 2025.
  • Average Intangibles over 5 years is $7.0 billion, with a median of $6.9 billion recorded in 2023.
  • The sharpest move saw Intangibles soared 36197.27% in 2021, then dropped 11.09% in 2025.
  • Year by year, Intangibles stood at $7.7 billion in 2021, then dropped by 6.31% to $7.2 billion in 2022, then fell by 4.16% to $6.9 billion in 2023, then decreased by 10.72% to $6.2 billion in 2024, then increased by 4.55% to $6.4 billion in 2025.
  • Business Quant data shows Intangibles for LLY at $6.4 billion in Q3 2025, $5.9 billion in Q2 2025, and $6.0 billion in Q1 2025.